León, Spain, November 9, 2026
Curia Global, Inc., a global contract research, development and manufacturing organization (CDMO), has announced the completion of a €5 million investment to expand its operations in León, Spain. The investment supports a new precision fermentation facility designed to strengthen biotechnology development, manufacturing scale-up and downstream processing capabilities. With the installation of new production equipment, the facility’s total capacity will increase to 58,000 litres, enhancing Curia’s ability to support pharmaceutical and biotechnology customers as their manufacturing programmes advance. The expansion includes new fermentation equipment, upstream processing (USP) and downstream processing (DSP) infrastructure, together with upgraded utility systems designed to provide reliable support for production operations. The project represents an important investment in Curia’s global manufacturing network and reflects the growing demand for flexible, scalable and dependable contract manufacturing services. The León facility serves customers across the pharmaceutical, biotechnology, cosmetics, agriculture and food industries, making the expansion relevant to several sectors that depend on advanced fermentation technologies.
€5 Million Investment Strengthens Fermentation Operations
The completed €5 million expansion project establishes a new precision fermentation facility at Curia’s León manufacturing site. The investment was designed to increase production capacity while improving the infrastructure required for biotechnology development and manufacturing scale-up. The new building incorporates specialized fermentation equipment and processing systems that support optimized production workflows. A major component of the project is the installation of additional upstream processing (USP) and downstream processing (DSP) equipment. Upstream processing involves preparing biological production systems, including fermentation operations, to generate the desired product. Downstream processing covers the subsequent recovery, separation, purification and processing of the material produced during fermentation. Integrating these capabilities within the expanded facility is intended to support more efficient manufacturing operations and provide greater flexibility for customer programmes. Curia has also upgraded essential site utilities to ensure a reliable supply of the services required by the new production building. These improvements are important because fermentation manufacturing depends on consistent operating conditions and dependable infrastructure. Following the installation of the new equipment, the facility’s capacity will reach 58,000 litres, strengthening its ability to support development activities and larger-scale manufacturing requirements. The investment demonstrates Curia’s continued focus on expanding specialized production capabilities to meet evolving customer needs.
León Facility Supports Pharmaceutical and Biotechnology Manufacturing
Curia’s León facility specializes in biotechnology development, fermentation production and downstream processing for customers in multiple industries. Its capabilities are particularly relevant to pharmaceutical and biotechnology companies that require external manufacturing support during product development and scale-up. Fermentation is an important industrial technology used to produce a wide range of biological materials, including proteins, enzymes, metabolites and other specialized compounds, depending on the manufacturing process and product requirements. The ability to move from development-scale activities toward larger production volumes is an important consideration for companies advancing biotechnology programmes. Through the expansion, Curia aims to provide customers with additional manufacturing flexibility and infrastructure to support their programmes at different stages. The upgraded facility also supports customers in the cosmetics, agriculture and food industries, demonstrating the broader industrial applications of precision fermentation. Jamie Grabowski, President of Research and Development at Curia, said the investment would help the company provide customers with reliable manufacturing, operational efficiency and flexible capacity as their programmes progress. The company also emphasized that improvements to production equipment and essential utilities will establish a stronger foundation for sustained performance at the León site.
Advertisement
CDMO Expansion Strengthens Curia’s Global Network
The León investment forms part of Curia’s wider strategy to strengthen its global contract development and manufacturing organization (CDMO) network. The company operates more than 20 sites worldwide and employs over 3,000 people, supporting biopharmaceutical customers from early discovery through commercialization. Its service portfolio includes small-molecule development, generic active pharmaceutical ingredients (APIs), biologics, analytical services, regulatory support, drug-substance manufacturing and sterile fill-finish operations. By expanding fermentation and downstream processing infrastructure in Spain, Curia is increasing the manufacturing resources available to its customers while strengthening its European operational footprint. Investments in specialized manufacturing facilities are increasingly important as pharmaceutical and biotechnology companies seek reliable external partners for process development, technology transfer and production scale-up. The availability of appropriate equipment, qualified utilities and consistent manufacturing processes can help support efficient development programmes and dependable production operations. Curia’s latest investment therefore represents more than an increase in physical capacity; it is also a strategic enhancement of the infrastructure supporting its CDMO services. The expanded León facility is expected to strengthen the company’s ability to respond to customer requirements across pharmaceutical and other biotechnology-related industries.
Source: Curia Global press release
